TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04232878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVL-936
Description: CVL-936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVL-936
Description: CVL-936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVL-936
Description: CVL-936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVL-936
Description: CVL-936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVL-936
Description: CVL-936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVL-936
Description: CVL-936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVL-936
Description: CVL-936

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo matching CVL-936

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo matching CVL-936

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo matching CVL-936

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo matching CVL-936

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo matching CVL-936

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo matching CVL-936

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo matching CVL-936
Study: NCT02222961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIR 561 CL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04389346

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periapical surgery using autologous platelet aggregate
Description: PRF will be placed over the denuded root surface, following apicoectomy and before flap repositioning

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Periapical surgery without autologous platelet aggregate
Description: Flap will be repositioned following apicoectomy directly without placing any platelet aggregate
Study: NCT02028468

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hemiarthroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hemiarthroplasty
Study: NCT03447652

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination Rehabilitation
Description: Combination Group - includes both the resistance band and Biomechanical Ankle Platform System programs.
Study: NCT01366794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Macronutrients
Description: Glucose 330 kcal Protein 110 kcal Fat emulsion 110 kcal Mixed meal 550 kcal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Macronutrients
Description: Glucose 330 kcal Protein 110 kcal Fat emulsion 110 kcal Mixed meal 550 kcal
Study: NCT01818427

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infusion of 2 units of plasma
Description: infusion of 2 units of plasma
Study: NCT01658956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCSF administration on days 8 and 12 after chemotherapy
Study: NCT00488228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-regulation
Description: The current study involves a behavioral weight loss intervention tailored specifically to young adults. All participants receive calorie and activity prescriptions as well as training in behavior modification. In addition, one group receives training in self-regulation techniques using daily weighing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-regulation
Description: The current study involves a behavioral weight loss intervention tailored specifically to young adults. All participants receive calorie and activity prescriptions as well as training in behavior modification. In addition, one group receives training in self-regulation techniques using daily weighing.
Study: NCT02622711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DI
Description: Participants will be offered an individualized dietary counselling according to their lifestyle habits to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAI
Description: Participants will be offered an individualized physical activity counseling according to their lifestyle habits to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PADI
Description: Participants will be offered an individualized dietary and physical activity counseling to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LII
Description: Participants will be considered as control group. They will receive a general healthy counselling providing materials and guidelines available for the general public.
Study: NCT04124783

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooling Bolero
Description: A vest filled with a new material (not ice or a gel) that provides controlled cooling by absorbing heat
Study: NCT00363649

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-K562 cell vaccine
Description: Given by injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interferon alfa
Description: Given by injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given by injection
Study: NCT05188872

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-Pentixafor
Description: Each patient receive a single intravenous injection of 68Ga-Pentixafor, and undergo PET/CT scan within specified time.
Study: NCT00002597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flutamide
Description: Two 125 mg capsules (t.i.d., p.o.) beginning two months before RT and continuing until RT is completed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoladex
Description: 3.6 mg s.c. monthly x 4 beginning two months before RT and continuing until RT is completed. The 3-month preparation may be used instead of three separate monthly injections.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lupron
Description: 7.5 mg IM (intramuscular) monthly x 4 beginning two months before RT and continuing until RT is completed. The 3-month preparation may be used instead of three separate monthly injections.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: 46.8 Gy (1.8 Gy/day four to five times a week \[26 fx\]) to regional lymphatics followed by 19.8 Gy (1.8 Gy/day x 11 fx) for a total of 66.6 Gy to the prostate. Prostate only may be treated in defined circumstances.

Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Description: 46.8 Gy (1.8 Gy/day four to five times a week \[26 fx\]) to regional lymphatics followed by 19.8 Gy (1.8 Gy/day x 11 fx) for a total of 66.6 Gy to the prostate. Prostate only may be treated in defined circumstances.
Study: NCT03530488

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: intrauterine and intracervical instillation of 4 ml of lidocaine 2% diluted in 15 ml normal saline

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Office hystroscopy
Description: A rigid 3.5 mm hystroscope with an optic of 30 degrees was used. Normal saline solution was used as distension media, with 120 mmHg intrauterine pressure, Vaginoscopic approach, nocervical tenaculum or dilators used.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Office hystroscopy
Description: A rigid 3.5 mm hystroscope with an optic of 30 degrees was used. Normal saline solution was used as distension media, with 120 mmHg intrauterine pressure, Vaginoscopic approach, nocervical tenaculum or dilators used.
Study: NCT02940210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mediclore® (adhesion barrier)
Study: NCT02725398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buscopan
Description: Buscopan is administered by endoscopic nurse in the Buscopan group,and then recording the outcome measures.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Scopolamine
Description: Scopolamine is administered by endoscopic nurse in the Scopolamine group,and then recording the outcome measures.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: physiological saline
Description: Physiological saline is administered by endoscopic nurse in the physiological saline group,and then recording the outcome measures.
Study: NCT00946205

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic posterior rectopexy
Description: The rectum is mobilised down to the os coccygeus, then it is elevated cephalic and sutured with a multifilament suture to the presacral fascia just below the sacral promontory. The lateral stalks should be left intact.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic anterior mesh rectopexy
Description: The peritoneum is incised over the right side of the promontory. The incision is extended in an inverted J-form along the right side of rectum and over the deepest part of the pouch of Douglas. Denonvilliers fascia is incised and the rectovaginal (women)/rectovesical (men) septum is broadly opened. A prosthetic mesh (3 x 17 cm) is sutured with nonabsorbable sutures to the ventral aspect of the rectum in the rectovaginal/rectovesical septum and to the lateral seromuscular borders of rectum and fixed upon the promontory using a stapler. The posterior fornix of vagina (women)/floor of the bladder (men) is elevated and sutured to the anterior aspect of the mesh. The incised peritoneum is then closed over the mesh.
Study: NCT01712295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17% Salicylate with ethyl pyruvate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salicylates
Study: NCT02046447

Intervention type: DRUG
Intervention: Primary Cervical Dystonia (Trihexyphenidyl)
Description: After the baseline testing these subjects will receive a dose of trihexyphenidyl 2 mg an hour prior to the second functional magnetic resonance imaging (fMRI) scan. This is to test the change in cerebral blood flow based on blood-oxygen-level dependent (BOLD) contrast during a precision gripping task after administration of trihexyphenidyl compared to change in BOLD contrast during a precision gripping task. The subjects will be done with the study after the second MRI scan has been completed.

Intervention type: OTHER
Intervention: Controls Primary Cervical Dystonia (Trihexyphenidyl)
Description: These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.

Intervention type: OTHER
Intervention: DYT 1 Dystonia (Healthy Control)
Description: These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.

Intervention type: OTHER
Intervention: DYT 1 Dystonia
Description: These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
Study: NCT00907946

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NT 1 day before PCNL
Description: A bladder urine culture will be obtained prior to nephrostomy tube placement and antibiotic treatment will be initiated if necessary. A nephrostomy tube will be placed at least one day prior to surgery in the Vascular Interventional Radiology (VIR) suite under fluoroscopic or ultrasound guidance. The type of imaging will be determined by the radiologist at the time of procedure and documented. A renal pelvis urine culture will be obtained at the time of nephrostomy tube placement. If the culture is positive, the patients will be treated with appropriate antibiotics for at least one week prior to PCNL. If the culture is negative, the patient will be stratified into 2 groups:~1. Hydronephrosis present and/or stone greater than 2cm empiric antibiotics will be initiated.~2. If neither of the above criteria (a.) are met, and the urine culture is negative, no antibiotics will be administered except peri-operatively according to standard protocol.
Study: NCT04561167

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cuspal reduction in MOD cavity in endodontically treated teeth
Description: Not only the quality of endodontic treatment that affects the prognosis of the endodontically treated tooth, but the subsequent restorative treatment as well. Coverage, Endocrowns, Onlays, Inlays Restorations on Fracture Resistance of Endodontically Treated Molars, it was found that the worst results came to the inlay restorations and this was attributed to geometric form of preparation that exert a wedging force acting to split the tooth when under occlual stress however, onlay and full coverage direct the force along the long axis by overlaying the cusp tips and a portion of buccal and lingual surface thus opposing the wedging action created by internal design of restoration (Magne P and Belser C. et al 2003) That's why, choosing such a design as a comparator to the design of the cuspal reduction and further coverage (onlay) is crucial to show the importance of cuspal coverage for the indirect resin composite restoration in the endodontically treated teeth.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No cuspal reduction in MOD cavity in endodontically treated teeth
Description: In an invitro study done by (Ahmed Hamdy 2015) investigating the effect of Full The amount of lost internal tooth structure as well as the coronal hard tissue in an endodontically treated tooth is considered the main factors that make the tooth susceptible to biomechanical failure when compared to a vital tooth. (Guo J et al 2016) .
Study: NCT01157377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-214868
Description: AGN-214868 injected into the bladder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-214868
Description: AGN-214868 injected into the bladder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-214868
Description: AGN-214868 injected into the bladder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-214868
Description: AGN-214868 injected into the bladder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-214868
Description: AGN-214868 injected into the bladder.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-214868
Description: AGN-214868 injected into the bladder.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AGN-214868 placebo
Description: AGN-214868 placebo injected into the bladder.
Study: NCT03289806

Intervention type: PROCEDURE
Intervention: Samples of fibroblasts from Tenon's capsule
Study: NCT00372255

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influsplit SSW® 2005/2006
Description: Study influenza vaccine was administered intramuscularly in the non-dominant arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influsplit SSW® 2005/2006
Description: Study influenza vaccine was administered intramuscularly in the non-dominant arm
Study: NCT00958607

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Timing it Right Stroke Family Support Person Intervention
Description: Intervention delivered by a stroke support person (SSP) in-person during acute care \& by telephone during inpatient rehabilitation and community discharge. SSP provides support, information \& guidance and gives caregivers Stroke Family Support guide as a resource. SSP will have 1 contact with the caregiver during acute care and a 2nd contact during the last week of inpatient acute or rehabilitation care. The 1st contact while the caregiver is at home will occur 2-3 weeks after the stroke survivor has been discharged from inpatient care and then every four weeks until the caregiver passes the marker question. SSP will then encourage caregiver to contact them if they have any specific questions. The SSP will make one final contact about 8 weeks later
Study: NCT01309113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VAC BNO 1095 film coated tablets
Description: 3 dosages: Placebo, 10 mg of VAC BNO 1095 once daily in the morning, 10 mg of VAC BNO 1095 twice daily in the morning and in the evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VAC BNO 1095 film coated tablets
Description: 3 dosages: Placebo, 10 mg of VAC BNO 1095 once daily in the morning, 10 mg of VAC BNO 1095 twice daily in the morning and in the evening

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VAC BNO 1095 film coated tablets
Description: 3 dosages: Placebo, 10 mg of VAC BNO 1095 once daily in the morning, 10 mg of VAC BNO 1095 twice daily in the morning and in the evening
Study: NCT02856061

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pivotal Response Treatment
Description: Pivotal response treatment (PRT) is an empirically validated behavioral treatment for individuals with ASD that has its foundation in principles of Applied Behavioral Analysis. It was designed to improve social communication skills by addressing core deficits in social motivation or pivotal responses. By working specifically with each child's natural motivations, PRT focuses on naturalistic, functional skills, as opposed to rote skills. In this study, participants randomized to the PRT group will receive 6 hours of direct PRT, across three sessions per week, provided by Dr. Ventola's clinical team. Parents will have an additional one-hour session per week focused on PRT parent training using a practice-with-feedback model. Specific intervention goals in our target population include: Speech to respond to inquiries, Speech to inquire, Speech to comment, Reciprocal conversation, Monitor nonverbal information, and Perspective taking.
Study: NCT00958607

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-directed program
Description: Participants in this arm of the trial will have family caregivers self-direct their use of the Timing it Right Stroke Family Support guide. The research assistant will instruct the caregivers how to self-manage their support needs by providing instruction on how to use the guide, which has an additional section regarding self-management. Caregivers will also be instructed that the guide is organized according to the phases of a stroke survivors' recovery. They will be instructed to review the information in each chapter as it becomes relevant to their current situation
Study: NCT01900431

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sarilumab
Description: Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Pharmaceutical form: Tablet or Capsule; Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Pharmaceutical form: Tablet or Capsule; Route of administration: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Pharmaceutical form: Tablet or Capsule or Suspension; Route of administration: Orally or intravenously or intramuscular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Pharmaceutical form: Tablet or Capsule or Suspension; Route of administration: Orally or intravenously or intramuscular

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic/folinic acid
Description: Pharmaceutical form: Tablet or Capsule; Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic/folinic acid
Description: Pharmaceutical form: Tablet or Capsule; Route of administration: Oral

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Sarilumab)
Description: Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous
Study: NCT02467894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group-based Care
Description: There will be self-care activities, blood pressure measurements and other vitals, including discussion of specific topics initiated by the participants.
Study: NCT02539134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-935
Description: TAK-935 oral solution
Study: NCT03697083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reminders Through Association
Description: Participants receive 8 text messages asking them to think of a reminder cue that will help them remember to pick up the prescription and use the cue.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Participants receive 8 text messages asking them to think of where they plan to store their medication once they pick it up and to think about that location on their intended date of pickup.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baseline Control
Description: Participants receive 1 text message thanking participants for enrolling in the reminder program. Participants are not contacted further.
Study: NCT02539134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-935 placebo-matching oral solution